Potential new target for treatment of ovarian cancer identified
August 17th, 2010 - 4:26 pm ICT by ANIWashington, Aug 17 (ANI): Scientists have identified a potential new target for the treatment of ovarian cancer.
For the first time, Salt Inducible Kinase 2 (SIK2) has been found to play a critical role in cell division and to regulate the response of some ovarian cancers to chemotherapy.
Researchers reported findings from The University of Texas MD Anderson Cancer Center. The study adds to growing evidence that combination therapies targeting different phases of the cell division cycle are vital for optimal cancer treatment.
Researchers found that depleting SIK2 from ovarian cancers sensitized the cancer cells to paclitaxel, a commonly prescribed chemotherapeutic agent that inhibits cell division, making the drug more effective in stopping the cancer’s growth.
Levels of the SIK2 protein are increased in approximately 30 percent of ovarian cancers and are associated with poorer survival in women with the disease.
“There is a large window of opportunity to improve the effectiveness of existing chemotherapies by modifying the sensitivity of cancer cells to the drugs,” study senior author Robert C. Bast Jr said.
“In our search for proteins that are responsible for that sensitivity, we found that SIK2 was required for cell division and that its inhibition offers a novel approach to improving chemotherapy for ovarian cancer that deserves further study,” he added.
Although mitosis-inhibiting drugs are used successfully to treat a range of cancers, only about 50 percent of ovarian cancer patients respond to taxanes and it is not yet possible to identify in advance which patients will benefit. As a result, many patients receive taxanes arbitrarily as part of a combination of chemotherapy drugs.
“The discovery that SIK2 plays a role in cell cycle regulation is groundbreaking since to date it has been linked to cellular metabolism and energy balance,” Ahmed said. “In addition to improving the response of some cancer to taxane, our findings add support to emerging evidence that cancer cell metabolism and mitosis functions are coupled,” Ahmed Ashour Ahmed, member of the faculty at Oxford University said.
The findings were reported in the August issue of journal Cancer Cell. (ANI)
- Motor protein that blocks ovarian tumor growth found - Apr 27, 2011
- New drug shows promise against platinum resistant ovarian cancer - Oct 10, 2010
- New experimental drug slows down growth of ovarian cancer - Apr 16, 2011
- How ovarian cancer resists chemotherapy - Mar 03, 2011
- Gene makes ovarian cancer resistant to chemotherapy - Mar 03, 2011
- New discovery may help overcome taxane resistance in cancer - Jan 27, 2010
- New therapy shows promising result for HER2-positive metastatic disease - Oct 09, 2010
- New discovery may help in the fight against ovarian cancer - Feb 04, 2011
- Protein that promotes cancer found - Aug 21, 2010
- Cancer-promoting protein discovered (Lead) - Aug 21, 2010
- New way to kill cancer cells discovered - Sep 18, 2011
- Trio of drugs may help fight 'triple negative' breast cancer - Dec 11, 2010
- New ovarian and breast cancer treatments - Feb 23, 2010
- Indian-origin scientist's finding offers hope for advanced cancer patients - Apr 06, 2011
- Skin cancer pill shrinks tumour in 80 percent cases - Aug 26, 2010
Tags: anderson cancer center, cancer cells, cancer treatment, cellular metabolism, chemotherapies, chemotherapy drugs, combination therapies, energy balance, md anderson cancer, md anderson cancer center, ovarian cancer, ovarian cancer patients, ovarian cancers, robert c bast, robert c bast jr, target, taxane, texas md anderson, treatment of ovarian cancer, university of texas md anderson cancer center